Virginia Ruth  Sanzone net worth and biography

Virginia Sanzone Biography and Net Worth

Ms. Sanzone has served as our Corporate Vice President, General Counsel and Secretary since January 2018. Ms. Sanzone also serves as our Compliance Officer. Ms. Sanzone served as the Company’s Vice President, General Counsel from August of 2015 to January 2018. Prior to August of 2015, Ms. Sanzone held various roles at CareFusion and last served as Senior Vice President, Associate General Counsel - Business Segments & Americas.

What is Virginia Ruth Sanzone's net worth?

The estimated net worth of Virginia Ruth Sanzone is at least $628,331.58 as of August 8th, 2024. Ms. Sanzone owns 4,482 shares of ICU Medical stock worth more than $628,332 as of March 14th. This net worth approximation does not reflect any other investments that Ms. Sanzone may own. Additionally, Ms. Sanzone receives an annual salary of $622,200.00 as VP at ICU Medical. Learn More about Virginia Ruth Sanzone's net worth.

How old is Virginia Ruth Sanzone?

Ms. Sanzone is currently 49 years old. There are 3 older executives and no younger executives at ICU Medical. The oldest executive at ICU Medical is Mr. Christian B. Voigtlander, Chief Operating Officer, who is 56 years old. Learn More on Virginia Ruth Sanzone's age.

What is Virginia Ruth Sanzone's salary?

As the VP of ICU Medical, Inc., Ms. Sanzone earns $622,200.00 per year. There are 3 executives that earn more than Ms. Sanzone. The highest earning executive at ICU Medical is Mr. Vivek Jain, CEO & Chairman of the Board, who commands a salary of $1,260,000.00 per year. Learn More on Virginia Ruth Sanzone's salary.

How do I contact Virginia Ruth Sanzone?

The corporate mailing address for Ms. Sanzone and other ICU Medical executives is 951 CALLE AMANECER, SAN CLEMENTE CA, 92763. ICU Medical can also be reached via phone at (949) 366-2183 and via email at ir@icumed.com. Learn More on Virginia Ruth Sanzone's contact information.

Has Virginia Ruth Sanzone been buying or selling shares of ICU Medical?

Virginia Ruth Sanzone has not been actively trading shares of ICU Medical during the last quarter. Most recently, Virginia Ruth Sanzone sold 2,050 shares of the business's stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $144.11, for a transaction totalling $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares of the company's stock, valued at $645,901.02. Learn More on Virginia Ruth Sanzone's trading history.

Who are ICU Medical's active insiders?

ICU Medical's insider roster includes Elisha Finney (Director), David Greenberg (Director), Vivek Jain (CEO & Chairman of the Board), George Lopez (Director), Virginia Sanzone (VP), Robert Swinney (Director), Christian Voigtlander (COO), and Daniel Woolson (Corporate Vice President and General Manager, Infusion Systems). Learn More on ICU Medical's active insiders.

Are insiders buying or selling shares of ICU Medical?

In the last year, insiders at the medical instruments supplier sold shares 16 times. They sold a total of 93,897 shares worth more than $14,057,618.34. The most recent insider tranaction occured on January, 2nd when CEO Vivek Jain sold 1,373 shares worth more than $213,474.04. Insiders at ICU Medical own 6.7% of the company. Learn More about insider trades at ICU Medical.

Information on this page was last updated on 1/2/2025.

Virginia Ruth Sanzone Insider Trading History at ICU Medical

See Full Table

Virginia Ruth Sanzone Buying and Selling Activity at ICU Medical

This chart shows Virginia Ruth Sanzone's buying and selling at ICU Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k$0$200kTotal Insider BuyingTotal Insider Selling

ICU Medical Company Overview

ICU Medical logo
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Read More

Today's Range

Now: $140.19
Low: $137.62
High: $142.05

50 Day Range

MA: $157.96
Low: $130.05
High: $172.30

2 Week Range

Now: $140.19
Low: $93.36
High: $196.26

Volume

191,815 shs

Average Volume

234,440 shs

Market Capitalization

$3.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73